ISSN 1671-5411 CN 11-5329/R
Online Office
Current Issue
Blood lead level in Chinese adults with and without coronary artery disease
Shi-Hong LI, Hong-Ju ZHANG, Xiao-Dong LI, Jian CUI, Yu-Tong CHENG, Qian WANG, Su WANG, Chayakrit Krittanawong, Edward A El-Am, Rody G. Bou Chaaya, Xiang-Yu WU, Wei GU, Hong-Hong LIU, Xian-Liang YAN, Zhi-Zhong LI, Shi-Wei YANG, Tao SUN
2021, 18(11): 857-866.   doi: 10.11909/j.issn.1671-5411.2021.11.004
Abstract(33) FullText HTML(17) PDF (6)
Chronic kidney disease and risks of adverse clinical events in patients with atrial fibrillation
Si-Tong LI, Chao JIANG, Liu HE, Qi-Fan LI, Zuohan DING, Jia-Hui WU, Rong HU, Qiang LV, Xu LI, Chang-Qi JIA, Yan-Fei RUAN, Man NING, Li FENG, Rong BAI, Ri-Bo TANG, Xin DU, Jian-Zeng DONG, Chang-Sheng MA
2021, 18(11): 867-876.   doi: 10.11909/j.issn.1671-5411.2021.11.002
Abstract(36) FullText HTML(18) PDF (6)
Minimally invasive thoracoscopic left atrial appendage occlusion compared with transcatheter left atrial appendage closure for stroke prevention in recurrent nonvalvular atrial fibrillation patients after radiofrequency ablation: a prospective cohort study
Jian-Long WANG, Kuo ZHOU, Zheng QIN, Wan-Jun CHENG, Ling-Zhi ZHANG, Yu-Jie ZHOU
2021, 18(11): 877-885.   doi: 10.11909/j.issn.1671-5411.2021.11.001
Abstract(12) FullText HTML(6) PDF (1)
Clinical benefit of left atrial appendage closure in octogenarians
Yamen Mohrez, Steffen Gloekler, Steffen Schnupp, Wasim Allakkis, Xiao-Xia Liu, Monika Fuerholz, Johannes Brachmann, Stephan Windecker, Stephan Achenbach, Bernhard Meier, Caroline Kleinecke
2021, 18(11): 886-896.   doi: 10.11909/j.issn.1671-5411.2021.11.003
Abstract(499) FullText HTML(239) PDF (21)
Periprocedural complications and one-year outcomes after catheter ablation for treatment of atrial fibrillation in elderly patients: a nationwide Danish cohort study
Jesper Nielsen, Kristian Hay Kragholm, Sofie Brix Christensen, Arne Johannessen, Christian Torp-Pedersen, Steen Buus Kristiansen, Peter Karl Jacobsen, Peter Steen Hansen, Mogens Stig Djurhus, Christoffer Polcwiartek, Peter Søgaard, Anna Margrethe Thøgersen, Uffe Jakob Ortved Gang, Ole Dan Jørgensen, Filip Lyng Lindgren, Sam Riahi
2021, 18(11): 897-907.   doi: 10.11909/j.issn.1671-5411.2021.11.005
Abstract(10) FullText HTML(5) PDF (1)
Biomarkers in the clinical management of patients with atrial fibrillation and heart failure
Ioanna Koniari, Eleni Artopoulou, Dimitrios Velissaris, Mark Ainslie, Virginia Mplani, Georgia Karavasili, Nicholas Kounis, Grigorios Tsigkas
2021, 18(11): 908-951.   doi: 10.11909/j.issn.1671-5411.2021.11.010
Abstract(133) FullText HTML(59) PDF (13)
COVID-19 vaccine safety surveillance and emerging concerns of vaccine-induced immune thrombotic thrombocytopenia
Shyh Poh Teo
2021, 18(11): 952-956.   doi: 10.11909/j.issn.1671-5411.2021.11.006
Abstract(14) FullText HTML(7) PDF (5)
Endovascular interventions may save limbs in elderly subjects with severe lower extremity arterial disease
Min-I SU, Cheng-Wei LIU
2021, 18(11): 957-967.   doi: 10.11909/j.issn.1671-5411.2021.11.007
Abstract(38) FullText HTML(19) PDF (5)
Coronary stent fracture in an octogenarian patient: from bad to worse
Andreas S. Triantafyllis, Petros N. Fountoulakis, Georgios Charalampidis, Konstantinos Kotinas, Pavlos Tsinivizov, Dimitrios Varvarousis, Andreas Giannakopoulos, Sofia Apollonatou, Areti Stefanidou, Stamatios Chatzopoulos, Dimitrios Tsiptsios, Konstantinos Tsamakis, Konstantinos Kyfnidis, Leonidas E. Poulimenos
2021, 18(11): 968-972.   doi: 10.11909/j.issn.1671-5411.2021.11.009
Abstract(34) FullText HTML(17) PDF (4)
Gastroprotection during long-term dual antiplatelet therapy: to give or not to give?
Francesco Sbrana, Andrea Ripoli, Beatrice Dal Pino
2021, 18(11): 973-974.   doi: 10.11909/j.issn.1671-5411.2021.11.008
Abstract(10) FullText HTML(5) PDF (2)
Online First
Xi WANG, Dong-Kai SHAN, Guan-Hua DOU, Yi-Pu DING, Jing JING, He-Bin CHE, Jun-Jie YANG, Yun-Dai CHEN
 doi: 10.11909/j.issn.1671-5411.2021.12.001
Abstract(174) FullText HTML(86) PDF (19)
 BACKGROUND  Lipoprotein(a) [Lp(a)] has been closely related to coronary atherosclerosis and might affect perivascular inflammation due to its proinflammatory properties. However, there are limited data about Lp(a) and related perivascular inflammation on coronary atheroma progression. Therefore, this study aimed to investigate the associations between Lp(a) and the perivascular fat attenuation index (FAI) with coronary atheroma progression detected by coronary computed tomography angiography (CCTA).  METHODS  Patients who underwent serial CCTA examinations without a history of revascularization and with available data for Lp(a) within one month before or after baseline and follow-up CCTA imaging scans were considered to be included. CCTA quantitative analyses were performed to obtain the total plaque volume (TPV) and the perivascular FAI. Coronary plaque progression (PP) was defined as a ≥ 10% increase in the change of the TPV at the patient level or the presence of new-onset coronary atheroma lesions. The associations between Lp(a) or the perivascular FAI with PP were examined by multivariate logistic regression.  RESULTS  A total of 116 patients were ultimately enrolled in the present study with a mean CCTA interscan interval of 30.80 ± 13.50 months. Among the 116 patients (mean age: 53.49 ± 10.21 years, males: 83.6%), 32 patients presented PP during the follow-up interval. Lp(a) levels were significantly higher among PP patients than those among non-PP patients at both baseline [15.80 (9.09−33.60) mg/dL vs. 10.50 (4.75−19.71) mg/dL, P = 0.029] and follow-up [20.60 (10.45−34.55) mg/dL vs. 8.77 (5.00−18.78) mg/dL, P = 0.004]. However, there were no differences in the perivascular FAI between PP group and non-PP group at either baseline or follow-up. Multivariate logistic regression analysis showed that elevated baseline Lp(a) level (OR = 1.031, 95% CI: 1.005−1.058, P = 0.019) was an independent risk factor for PP after adjustment for other conventional variables.  CONCLUSIONS  Lp(a) was independently associated with coronary atheroma progression beyond low-density lipoprotein cholesterol and other conventional risk factors. Further studies are warranted to identify the inflammation effect exhibited as the perivascular FAI on coronary atheroma progression.
Odong Christopher, Xing-Feng XU, Yi-Fen LIN, Shao-Zhao ZHANG, Yi-Quan HUANG, Xiang-Bin ZHONG, Zhen-Yu XIONG, Tara Scarlett Rosalyn CHEN, Chao-Guang XU, Xiao-Dong ZHUANG, Xin-Xue LIAO
 doi: 10.11909/j.issn.1671-5411.2021.12.003
Abstract(378) FullText HTML(184) PDF (40)
 BACKGROUND  Cystatin C (CysC) is a cysteine protease inhibitor involved in proteins catabolism and plays an essential role in human vascular pathophysiology. CysC may also increase the risk of aortic stenosis (AS), but limited studies have reported on this association. This study aimed to investigate if elevated serum CysC levels are associated with hemodynamically significant AS.  METHODS  Serum CysC levels were estimated in 4,791 participants, samples were collected in 1990−1992. The study population was divided into quintile groups. Follow-up continued in 2011–2013 when participants returned for echocardiography examination. Incidence of aortic valve disease (AVD) was ascertained by Doppler echocardiography through the end of 2013. AVD defined in hemodynamic progression was assessed and classified as aortic sclerosis, mild stenosis, and moderate-to-severe stenosis.  RESULTS  Overall, a total of 4,791 participants (mean age: 54.8 ± 5.0 years, females: 57.6%, blacks: 8.2%) were included in this study. During a follow-up of 21 years, we identified 736 cases (15.4%) of aortic sclerosis, 194 cases (4.0%) of mild stenosis, and 42 cases (0.7%) of moderate-to-severe stenosis. Compared with serum CysC levels within individual quintile groups, the odds ratio (OR) was per standard deviation associated with an increased incidence of AVD (OR = 1.15, 95% CI: 1.05−1.26, P = 0.002).  CONCLUSIONS  In this large population-based study, an increased serum CysC levels is independently associated with the incidence of hemodynamically significant AS. However, this association appears not to extend to patients with extremely high serum CysC levels and necessitate further investigation.
Ahmed Maraey, Mahmoud Salem, Nabila Dawoud, Mahmoud Khalil, Ahmed Elzanaty, Hadeer Elsharnoby, Ahmed Younes, Ahmed Hashim, Amit Alam
 doi: 10.11909/j.issn.1671-5411.2021.12.005
Abstract(95) FullText HTML(42) PDF (3)
 BACKGROUD  Acute heart failure with preserved ejection fraction (HFpEF) is a common but poorly studied cause of hospital admissions among nonagenarians. This study aimed to evaluate predictors of thirty-day readmission, in-hospital mortality, length of stay, and hospital charges in nonagenarians hospitalized with acute HFpEF.  METHODS  Patients hospitalized between January 2016 and December 2018 with a primary diagnosis of diastolic heart failure were identified using ICD-10 within the Nationwide Readmission Database. We excluded patients who died in index admission, and discharged in December each year to allow thirty-day follow-up. Univariate regression was performed on each variable. Variables with P-value < 0.2 were included in the multivariate regression model.  RESULTS  From a total of 45,393 index admissions, 43,646 patients (96.2%) survived to discharge. A total of 7,437 patients (15.6%) had a thirty-day readmission. Mean cost of readmission was 43,265 United States dollars (USD) per patient. Significant predictors of thirty-day readmission were chronic kidney disease stage III or higher [adjusted odds ratio (aOR) = 1.20, 95% CI: 1.07−1.34, P = 0.002] and diabetes mellitus (aOR = 1.18, 95% CI: 1.07−1.29, P = 0.001). Meanwhile, female (aOR = 0.90, 95% CI: 0.82−0.99, P = 0.028) and palliative care encounter (aOR = 0.27, 95% CI: 0.21−0.34, P < 0.001) were associated with lower odds of readmission. Cardiac arrhythmia (aOR = 1.46, 95% CI: 1.11−1.93, P = 0.007) and aortic stenosis (aOR = 1.36, 95% CI: 1.05−1.76, P = 0.020) were amongst predictors of in-hospital mortality.  CONCLUSIONS  In nonagenarians hospitalized with acute HFpEF, thirty-day readmission is common and costly. Chronic comorbidities predict poor outcomes. Further strategies need to be developed to improve the quality of care and prevent the poor outcome in nonagenarians.
Latest News
We would delightedly report that the 2020 SCI impact factor of Journal of Geriatric Cardiology(JGC,ISSN 1671-5411/ CN 11-5329/R) has increased from 2.491 to 3.327, according to the 2020 Journal Citation Reports (InCites, Clarivate Analytics), ranking 33/53 and 65/142 in the fields of Geriatrics & Gerontology and Cardiac & Cardiovascular Systems, respectively. Show more
Show more
Li-Yuan MA, Wei-Wei CHEN, Run-Lin GAO, Li-Sheng LIU, Man-Lu ZHU, Yong-Jun WANG, Zhao-Su WU, Hui-Jun LI, Dong-Feng GU, Yue-Jin YANG, Zhe ZHENG, Sheng-Shou HU
doi: 10.11909/j.issn.1671-5411.2020.01.001
Press releases Press office Contact us